Damora Therapeutics, Inc. 8-K

What Happened
Damora Therapeutics, Inc. (DMRA) announced the completion of its redomestication from Delaware to the Cayman Islands pursuant to a Plan of Conversion approved by shareholders and effective July 16, 2026. The Certificate of Conversion became effective at 4:45 p.m. EDT on July 16, 2026, and the company’s Cayman memorandum and articles of association were filed the same day. The company’s ordinary shares began trading with a new CUSIP (G2646Y104) at the open of trading on July 20, 2026 under the existing Nasdaq symbol “DMRA.” On July 16, 2026 the company also entered into new indemnification agreements with its directors and executive officers, replacing prior indemnity arrangements.

Key Details

• Special meeting approving the redomestication was held February 9, 2026; the definitive proxy described the transaction.
• Conversion mechanics effective July 16, 2026: each outstanding common share converted 1-for-1 into a Cayman ordinary share; preferred shares, options, and RSUs converted or continued on a 1-for-1 basis with no change to terms.
• New company governance: internal affairs now governed by Cayman Islands law and the Cayman Articles; Series A/B/C preferred shares were designated under Cayman certificates of designation effective July 16, 2026.
• Indemnification agreements entered July 16, 2026 provide for indemnification and advancement of expenses for directors and officers; the form is filed as Exhibit 10.1. Press release announcing consummation issued July 17, 2026 (Exhibit 99.1).

Why It Matters
Redomestication changes the company’s legal jurisdiction and governing documents (Delaware law → Cayman Islands law), which can affect corporate governance and certain shareholder rights; the filing notes that some shareholder rights were changed and refers investors to the Proxy Statement (Proposal No. 3) and the Plan of Conversion/Cayman Articles for details. Operationally and financially the company says the redomestication did not change its business, management, contracts, tax treatment (remains treated as a U.S. corporation for federal tax purposes), or produce material accounting effects, and trading continued under the same ticker with a new CUSIP. The new indemnification agreements formalize protections for directors and officers, which can be relevant to governance and management risk considerations. Investors should review the Plan of Conversion, Cayman Articles, and the proxy disclosure for specifics on any changes to shareholder rights.